Core Viewpoint - Company Gilead Sciences-B (01672) announced a share buyback plan, intending to repurchase 200,000 shares at a cost of approximately HKD 1.9327 million by October 31, 2025 [1] Summary by Category - **Company Actions** - Gilead Sciences-B plans to repurchase 200,000 shares [1] - The total expenditure for the buyback is estimated at HKD 1.9327 million [1]

格隆汇10月31日丨歌礼制药-B(01672.HK)公告，10月31日耗资193.3万港元回购20万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年10月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫 ...

Market Overview - The Hong Kong stock market indices continued to decline in the afternoon, reflecting a low market sentiment and recording a three-day pullback [1] - The Hang Seng Index fell by 1.43%, closing below the 26,000-point mark, while the Hang Seng China Enterprises Index dropped by 1.91% and the Hang Seng Tech Index decreased by 2.37%, also falling below 6,000 points [1] Sector Performance - Major technology stocks collectively weakened, negatively impacting market sentiment, with Alibaba down by 4%, Tencent falling over 3%, and other companies like Kuaishou, Baidu, JD.com, and Xiaomi declining by more than 2% [1] - Large financial stocks, including banks, insurance, and brokerage firms, mostly experienced declines, with China CRRC dropping over 10%, leading to declines in China Railway and China Railway Construction, while Everbright Securities fell by 6% and China People's Insurance Group decreased by 5.8% [1] - Semiconductor stocks were weak throughout the day, with leading company SMIC down by over 5%, alongside declines in military, automotive, coal, gold, real estate, aviation, photovoltaic, and Apple concept stocks [1] Innovation and Growth Sectors - Multiple catalysts ignited the innovative drug sector, with 3SBio surging over 11%, leading the gains, followed by Innovent Biologics rising nearly 8%, and Fosun Pharma and Ascletis Pharma also showing strong performance [1] - Some sectors such as education, home appliances, and gaming saw partial increases, with online education leader New Oriental rising over 2% [1]

Core Viewpoint - The company, Gilead Sciences-B (01672), has selected ASC36 as a clinical development candidate, which is expected to be a best-in-class monthly subcutaneous injection amylin receptor agonist for obesity treatment, with plans to submit an IND to the FDA by Q2 2026 [1] Group 1: Product Development - ASC36 is developed using Gilead's AI-assisted drug discovery and long-acting drug development platform technology [1] - The optimized design of ASC36 allows for a longer apparent half-life and higher bioavailability per milligram of peptide, supporting monthly subcutaneous administration with an injection volume not exceeding 1 milliliter [1] - These optimized characteristics are expected to reduce costs in large-scale production [1] Group 2: Market Reaction - Following the announcement, Gilead's stock rose over 4%, specifically by 4.62%, reaching HKD 9.74, with a trading volume of HKD 12.814 million [1]

人民财讯10月30日电，歌礼制药10月30日在港交所公告，已选定一款有望成为同类最佳每月一次皮下注 射胰淀素(amylin)受体激动剂ASC36作为临床开发候选药物。歌礼预计将于2026年第二季度向美国食品 药品监督管理局(FDA)递交ASC36治疗肥胖症的新药临床试验申请(IND)。 ...

Core Insights - The company has selected ASC36 as a clinical development candidate, which is expected to be a best-in-class monthly subcutaneous injection amylin receptor agonist for obesity treatment [1][2] - ASC36 is developed using the company's AI-assisted drug discovery and ultra-long-acting drug development platforms, featuring optimized properties for longer half-life and higher bioavailability [1] - The company plans to submit an Investigational New Drug (IND) application to the FDA in Q2 2026 [1] Drug Development and Efficacy - ASC36 has an observed half-life of approximately 15 days in non-human primate studies, which is three times longer than petrelintide, supporting the potential for monthly dosing in humans [2] - In diet-induced obesity rat studies, ASC36 demonstrated a weight reduction of 10.01%, compared to 5.25% for petrelintide, indicating a 91% relative improvement in weight loss efficacy [2] - The optimized characteristics of ASC36 may lead to lower manufacturing costs and improved dosing regimens for patients [2]

Core Insights - The company has selected ASC36 as a promising monthly subcutaneous injection amylin receptor agonist for clinical development, with plans to submit an IND to the FDA by Q2 2026 [1] Group 1: Product Development - ASC36 is developed using the company's AI-assisted structure-based drug discovery and ultra-long-acting platform technologies, achieving a longer apparent half-life and higher bioavailability per milligram of peptide [1] - The optimized characteristics of ASC36 support monthly subcutaneous administration with an injection volume not exceeding 1 milliliter, leading to cost advantages in manufacturing [1] Group 2: Clinical Research - In head-to-head studies with non-human primates, ASC36 demonstrated an average observed half-life of approximately 15 days, three times longer than petrelintide, indicating potential for monthly dosing in humans [2] - In diet-induced obesity rat studies, ASC36 resulted in a weight reduction of 10.01%, compared to 5.25% for petrelintide, representing a 91% relative improvement in weight loss efficacy [2]

Core Viewpoint - The company has selected ASC36 as a promising candidate for clinical development, expected to be submitted for FDA approval in Q2 2026 for obesity treatment [1] Group 1: Product Development - ASC36 is an amylin receptor agonist developed using AI-assisted structure-based drug discovery and ultra-long-acting platform technologies [1] - The optimized design of ASC36 allows for a longer apparent half-life and higher bioavailability per milligram, supporting monthly subcutaneous administration with a volume not exceeding 1 milliliter [1] - The scalability advantages in manufacturing are highlighted, indicating lower production costs for ASC36 [1] Group 2: Clinical Research Findings - In head-to-head studies with non-human primates, ASC36 demonstrated an average observed half-life of approximately 15 days, three times longer than petrelintide, supporting its potential for monthly dosing in humans [2] - In diet-induced obesity rat studies, ASC36 achieved a weight reduction of 10.01%, compared to 5.25% for petrelintide, indicating a relative improvement of 91% in weight loss effectiveness [2] - The superior weight loss effect per milligram of peptide may further enhance the cost-effectiveness of ASC36 in large-scale production [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 歌禮選定同類最佳每月一次皮下注射胰淀素受體激動劑 ASC36進入臨床開發階段 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈，已選定一款有望成為同類最佳每月一 次皮下注射胰淀素(amylin)受體激動劑ASC36作為臨床開發候選藥物。歌禮預計 將於2026年第二季度向美國食品藥品監督管理局(FDA)遞交ASC36治療肥胖症的 新藥臨床試驗申請(IND)。 | 組別 | 給藥方案 | 相對基線的 | 較petrelintide的 | | --- | --- | --- | --- | | | | 總體重變化 | 減重效果相對提升 | | 服 ...